Literature DB >> 32805396

MITOCHONDRIAL CHOLESTEROL AND CANCER.

Carmen Garcia-Ruiz1, Laura Conde de la Rosa2, Vicent Ribas2, Jose C Fernandez-Checa1.   

Abstract

Cholesterol is a crucial component of membrane bilayers that determines their physical and functional properties. Cells largely satisfy their need for cholesterol through the novo synthesis from acetyl-CoA and this demand is particularly critical for cancer cells to sustain dysregulated cell proliferation. However, the association between serum or tissue cholesterol levels and cancer development is not well established as epidemiologic data do not consistently support this link. While most preclinical studies focused on the role of total celular cholesterol, the specific contribution of the mitochondrial cholesterol pool to alterations in cancer cell biology has been less explored. Although low compared to other bilayers, the mitochondrial cholesterol content plays an important physiological function in the synthesis of steroid hormones in steroidogenic tissues or bile acids in the liver and controls mitochondrial function. In addition, mitochondrial cholesterol metabolism generates oxysterols, which in turn, regulate multiple pathways, including cholesterol and lipid metabolism as well as cell proliferation. In the present review, we summarize the regulation of mitochondrial cholesterol, including its role in mitochondrial routine performance, cell death and chemotherapy resistance, highlighting its potential contribution to cancer. Of particular relevance is hepatocellular carcinoma, whose incidence in Western countries had tripled in the past decades due to the obesity and type II diabetes epidemic. A better understanding of the role of mitochondrial cholesterol in cancer development may open up novel opportunities for cancer therapy.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Mevalonate pathway; StARD1; chemotherapy; free cholesterol; hepatocellular carcinoma; oxysterols

Mesh:

Substances:

Year:  2020        PMID: 32805396      PMCID: PMC7882000          DOI: 10.1016/j.semcancer.2020.07.014

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   17.012


  127 in total

Review 1.  High-flux mitochondrial cholesterol trafficking, a specialized function of the adrenal cortex.

Authors:  Colin Jefcoate
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

2.  Conditional steroidogenic cell-targeted deletion of TSPO unveils a crucial role in viability and hormone-dependent steroid formation.

Authors:  Jinjiang Fan; Enrico Campioli; Andrew Midzak; Martine Culty; Vassilios Papadopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-26       Impact factor: 11.205

Review 3.  Cholesterol, the central lipid of mammalian cells.

Authors:  Frederick R Maxfield; Gerrit van Meer
Journal:  Curr Opin Cell Biol       Date:  2010-06-02       Impact factor: 8.382

4.  Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort.

Authors:  Eric J Jacobs; Christina C Newton; Michael J Thun; Susan M Gapstur
Journal:  Cancer Res       Date:  2011-02-22       Impact factor: 12.701

5.  Endoplasmic Reticulum Stress-Induced Upregulation of STARD1 Promotes Acetaminophen-Induced Acute Liver Failure.

Authors:  Sandra Torres; Anna Baulies; Naroa Insausti-Urkia; Cristina Alarcón-Vila; Raquel Fucho; Estel Solsona-Vilarrasa; Susana Núñez; David Robles; Vicent Ribas; Leslie Wakefield; Markus Grompe; M Isabel Lucena; Raul J Andrade; Sanda Win; Tin A Aung; Neil Kaplowitz; Carmen García-Ruiz; Jose C Fernández-Checa
Journal:  Gastroenterology       Date:  2019-04-25       Impact factor: 22.682

Review 6.  Cytochrome P450s in the synthesis of cholesterol and bile acids--from mouse models to human diseases.

Authors:  Gregor Lorbek; Monika Lewinska; Damjana Rozman
Journal:  FEBS J       Date:  2011-12-22       Impact factor: 5.542

7.  Bile acids promote diethylnitrosamine-induced hepatocellular carcinoma via increased inflammatory signaling.

Authors:  Lina Sun; Kevin Beggs; Prachi Borude; Genea Edwards; Bharat Bhushan; Chad Walesky; Nairita Roy; Michael W Manley; Sumedha Gunewardena; Maura O'Neil; Hua Li; Udayan Apte
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-05-05       Impact factor: 4.052

8.  The pathophysiology and genetics of congenital lipoid adrenal hyperplasia.

Authors:  H S Bose; T Sugawara; J F Strauss; W L Miller
Journal:  N Engl J Med       Date:  1996-12-19       Impact factor: 91.245

9.  Transport of cholesterol into mitochondria is rate-limiting for bile acid synthesis via the alternative pathway in primary rat hepatocytes.

Authors:  William M Pandak; Shunlin Ren; Dalila Marques; Elizabeth Hall; Kaye Redford; Darrell Mallonee; Patricia Bohdan; Douglas Heuman; Gregorio Gil; Phillip Hylemon
Journal:  J Biol Chem       Date:  2002-10-03       Impact factor: 5.157

Review 10.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

View more
  3 in total

Review 1.  Understanding the Role of Metabolic Syndrome as a Risk Factor for Hepatocellular Carcinoma.

Authors:  Norberto C Chavez-Tapia; Sofía Murúa-Beltrán Gall; Ana Luisa Ordoñez-Vázquez; Natalia Nuño-Lambarri; Paulina Vidal-Cevallos; Misael Uribe
Journal:  J Hepatocell Carcinoma       Date:  2022-07-05

Review 2.  The Mevalonate Pathway, a Metabolic Target in Cancer Therapy.

Authors:  Borja Guerra; Carlota Recio; Haidée Aranda-Tavío; Miguel Guerra-Rodríguez; José M García-Castellano; Leandro Fernández-Pérez
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

Review 3.  Linking Late Endosomal Cholesterol with Cancer Progression and Anticancer Drug Resistance.

Authors:  Mai K L Nguyen; Jaimy Jose; Mohamed Wahba; Marc Bernaus-Esqué; Andrew J Hoy; Carlos Enrich; Carles Rentero; Thomas Grewal
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.